Join our daily newsletter At The Bell to receive exclusive market insights
It’s been a busy line-up for Firebrick Pharma (ASX:FRE) during 2025’s March quarter, with the company launching its Nasodine iodine nasal spray in Singaporean pharmacies, seeing solid online sales in the U.S., prepping expansion into Fiji and the South Pacific, and now eyeing a Philippines launch next year.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The retail move into Singapore was of particular importance, with initial stocks of Nasodine distributed to specific Guardian pharmacies in January.
This increased to 54 pharmacies the following month, including five new openings at Changi airport and a virtual training course for Guardian pharmacies marketing the product.
By the end of March, up to 125 pharmacies in Singapore are now selling Nasodine, supported by a range of marketing and in-store promotions organised through Firebrick’s marketing partner, Innorini Life Sciences.
Firebrick also reported marketing success in the U.S. where online orders grew 44% in the third quarter and were up 135% compared to first-quarter hauls.
Alongside this, Q3 unit sales have reportedly increased 81% compared to Q2 and 203% compared to Q1, with these figures reflecting the increasing underlying adoption of Nasodine in the U.S. A paid influencer marketing program which ran from December to January also helped, as did a “buy one, get one free” program which was offered between January and March 2025.
Expansion into other markets was also a watchword; Firebrick executed a License and Distribution Agreement with Makans covering Fiji and the South Pacific.
The company also continued major preparations for its launch into the Philippines.
The latter included the manufacture in February of Nasodine at Hizon Pharmaceuticals in Manilla, under Firebrick’s supervision.
The resulting product will receive stability testing for six months (expected for completion by August) followed by the completion of a registration dossier.
Once these test results come in, they should enable Firebrick’s licensing partner SV More to file for approval of Nasodine by the Philippines Food and Drug Administration (PFDA), opening the door to a launch in mid-2026.
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
Financial news was also positive for the company during the March quarter: It secured a $1.1 million strategic investment from Pharma Nutria N.A., Inc., an entity that forms part of the SV More Group of Companies, including Firebrick’s Philippines licensing partner, SV More Pharma Corporation.
FRE has been trading at 7.9 cents.
Join the discussion: See what HotCopper users are saying about Firebrick Pharma and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
